Stockhead’s Ashtyn Hiron sits down with Optiscan (ASX:OIL) CEO And Managing Director Dr. Camile Farah to get the short end of the long story on the company’s latest news.
Optiscan received a $3 million dollar grant to work on its second-generation gastrointestinal endo microscope, validating the company’s technology and helping to commercialise its platform.
Optiscan has been working behind the scenes for years on a new platform for gastrointestinal microscopy, including using Artificial Intelligence to enhance the electronics allowing clinicians to diagnose and treat patients in real time.
Tune in to hear Optiscan’s Dr. Camile Farah on why the grant is important, how the technology will help patients, what comes next for Optiscan and more.
The post Long Shortz with Optiscan: Optiscan optimises AI in its fight against GI baddies appeared first on Stockhead.
